I am saying that making the transcript public may not simple matter. It may need FDA's permission due to confidentiality and might end up being redacted (what would say then?). I can be wrong about this - would not be the first time. I am fairly confident that Loanranger is willing to educate me.
On related note: have you seen any company making public EOP2 meeting transcript? Highlights as in: "FDA gave go ahead for P3 with these endpoints (plus possibly some safety related requirements)", but whole transcript? BTW: we already happen to know what endpoints for brilacidin in SOM are going to be, don't we.
News 
Market Data 
Discover 
AI
